An updated review of infliximab biosimilar, CT-P13, in the treatment of immune-mediated inflammatory diseases

被引：4
|
作者：
Hong, Seung Wook [1 ]
Kim, Yong-Gil [2 ]
Ye, Byong Duk [1 ,3 ]
机构：
[1] Univ Ulsan, Asan Med Ctr, Dept Gastroenterol, Coll Med, Seoul, South Korea
[2] Univ Ulsan, Asan Med Ctr, Dept Rheumatol, Coll Med, Seoul, South Korea
[3] Univ Ulsan, Inflammatory Bowel Dis Ctr, Asan Med Ctr, Coll Med, Seoul, South Korea
来源：
IMMUNOTHERAPY | 2020年 / 12卷 / 09期
关键词：
ankylosing spondylitis; arthritis; Crohn's disease; CT-P13; efficacy; infliximab; psoriasis; rheumatoid arthritis; safety; spondylitis; ulcerative colitis; ACTIVE RHEUMATOID-ARTHRITIS; NECROSIS-FACTOR-ALPHA; DOUBLE-BLIND; CROHNS-DISEASE; BOWEL-DISEASE; INNOVATOR INFLIXIMAB; MAINTENANCE THERAPY; INDUCTION THERAPY; PHASE-III; ANKYLOSING-SPONDYLITIS;
D O I：
10.2217/imt-2020-0086
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
The introduction of anti-TNFs, such as infliximab (IFX), has revolutionized the treatment of immune-mediated inflammatory diseases. Anti-TNF agents have shown outstanding efficacy and long-term improvement of clinical outcomes, but the cost has been relatively high. Out of this concern, several 'biosimilar' drugs of anti-TNF agents have been developed. CT-P13, the first biosimilar of reference IFX, was approved by the European Medicines Agency and licensed by the US FDA for use in all indications of IFX. This updated review summarizes all aspects of CT-P13, including pharmacology and pharmacokinetics, and evaluates its efficacy, safety and immunogenicity for all indications based on the results of the latest clinical trials as well as on real-world experiences.
引用
收藏
页码：609 / 623
页数：15
相关论文
共 50 条
  • [41] Infliximab biosimilar CT-P13 is effective and safe in treating inflammatory bowel diseases: a real-life multicenter, observational study in Italian primary inflammatory bowel disease centers
    Tursi, Antonio
    Mocci, Giammarco
    Faggiani, Roberto
    Allegretta, Leonardo
    Della Valle, Nicola
    Forti, Giacomo
    Franceschi, Marilisa
    Ferronato, Antonio
    Gallina, Sara
    Larussa, Tiziana
    Luzza, Francesco
    Lorenzetti, Roberto
    Penna, Antonio
    Rodino, Stefano
    Sebkova, Ladislava
    Lauria, Angelo
    Piergallini, Simona
    Pranzo, Giuseppe
    Ricciardelli, Cristina
    Zampaletta, Costantino
    Elisei, Walter
    Picchio, Marcello
    ANNALS OF GASTROENTEROLOGY, 2019, 32 (04): : 392 - 399
  • [42] Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases
    Jonathan Kay
    Raymond K. Cross
    Steven R. Feldman
    Younjin Park
    Stephen B. Hanauer
    Advances in Therapy, 2024, 41 : 509 - 533
  • [43] Patients' perspectives after switching from infliximab to biosimilar CT-P13 in patients with inflammatory bowel disease: A 12-month prospective cohort study
    Petitdidier, Nicolas
    Tannoury, Jenny
    de'Angelis, Nicola
    Gagniere, Charlotte
    Hulin, Anne
    Rotkopf, Hugo
    Mesli, Farida
    Brunetti, Francesco
    Sobhani, Iradj
    Amiot, Aurelien
    DIGESTIVE AND LIVER DISEASE, 2019, 51 (12) : 1652 - 1660
  • [44] Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases
    Kay, Jonathan
    Cross Jr, Raymond K.
    Feldman, Steven R.
    Park, Younjin
    Hanauer, Stephen B.
    ADVANCES IN THERAPY, 2024, 41 (02) : 509 - 533
  • [45] Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody
    Isaacs, J. D.
    Cutolo, M.
    Keystone, E. C.
    Park, W.
    Braun, J.
    JOURNAL OF INTERNAL MEDICINE, 2016, 279 (01) : 41 - 59
  • [46] Switching from originator infliximab to biosimilar CT-P13 in real-life: The weight of patient acceptance
    Scherlinger, Marc
    Germain, Vincent
    Labadie, Celine
    Barnetche, Thomas
    Truchetet, Marie-Elise
    Bannwarth, Bernard
    Mehsen-Cetre, Nadia
    Richez, Christophe
    Schaeverbeke, Thierry
    JOINT BONE SPINE, 2018, 85 (05) : 561 - 567
  • [47] Real-world observational cohort study of treatment patterns and safety outcomes of infliximab biosimilar CT-P13 for the treatment of inflammatory bowel disease (CONNECT-IBD)
    Bokemeyer, Bernd
    Hlavaty, Tibor
    Allez, Matthieu
    Selema, Pamela
    Moosavi, Shahrzad
    Cadatal, Mary Jane
    Fowler, Heather
    Mueller, Markus
    Liau, Katherine F.
    Gisbert, Javier P.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2023, 23 (08) : 791 - 800
  • [48] Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience
    Ratnakumaran, Raguprakash
    To, Natalie
    Gracie, David J.
    Selinger, Christian P.
    O'Connor, Anthony
    Clark, Tanya
    Carey, Nicola
    Leigh, Katherine
    Bourner, Lynsey
    Ford, Alexander C.
    Hamlin, P. John
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2018, 53 (06) : 700 - 707
  • [49] Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease
    Bernard, Edmond-Jean
    Fedorak, Richard N.
    Jairath, Vipul
    DIGESTIVE DISEASES AND SCIENCES, 2020, 65 (08) : 2354 - 2372
  • [50] The Treatment with Interleukin 17 Inhibitors and Immune-Mediated Inflammatory Diseases
    Tiburca, Laura
    Bembea, Marius
    Zaha, Dana Carmen
    Jurca, Alexandru Daniel
    Vesa, Cosmin Mihai
    Ratiu, Ioana Adela
    Jurca, Claudia Maria
    CURRENT ISSUES IN MOLECULAR BIOLOGY, 2022, 44 (05) : 1851 - 1866
12345